Help protect your patients with T2D and established CVD
INVOKANA® is the only T2D pill approved to reduce the risk of heart attack, stroke, and cardiovascular death1
- As demonstrated in 6656 patients in the longest landmark cardiovascular outcomes program for an oral type 2 diabetes therapy1-3
Early (26 weeks) and sustained results1*
- The primary endpoint of the CANVAS Program (N=10,142) was 3-point MACE (heart attack, stroke, and CV death) for patients with T2D and established CVD or ≥2 risk factors for CVD2: HR=0.86 (95% CI: 0.75, 0.97); P=0.02 for superiority
- Cardiovascular outcomes trials for type 2 diabetes agents are powered to evaluate 3-point MACE5
*These results reflect the subgroup of patients from the CANVAS Program with established cardiovascular disease.
All 3 components positively contributed to the primary endpoint1*
CV=cardiovascular; CVD=cardiovascular disease; HR=hazard ratio; MACE=major adverse cardiovascular events; RRR=relative risk reduction; T2D=type 2 diabetes.
Use of background therapy for glycemic management and other control of risk factors was guided by best practice according to local guidelines.
Select baseline background therapies in patients with established CVD1
|RAAS inhibitor (ACEi/ARB)||79.8%|
|Calcium channel blocker||33.9%|
|GLP1 receptor agonist||3.7%|
ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; CVD=cardiovascular disease; DPP4=dipeptidyl peptidase-4; GLP1=glucagon-like peptide-1; MACE=major adverse cardiovascular events; MI=myocardial infarction; RAAS=renin-angiotensin-aldosterone system.
Select baseline characteristics1
|Duration of diabetes||13.2 years|
|eGFR||75.5 mL/min/1.73 m2|
|LDL cholesterol||85.1 mg/dL|
|Symptomatic atherosclerotic cardiovascular events|
|Hospitalization for unstable angina||10.9%|
|Peripheral vascular disease2||20.8%|
|Other comorbid conditions|
CVD=cardiovascular disease; MI=myocardial infarction.
†Cardioprotective benefits are defined as protection against MACE, including nonfatal MI, nonfatal stroke, and cardiovascular death.
Long-term cardiovascular outcomes trial at 338 weeks (Mahaffey et al)
The CANVAS Program was a double-blind comparison of the effects of INVOKANA® vs placebo from an integrated analysis of 2 large-scale trials (the CANVAS trial and the CANVAS-R trial) including 10,142 men and women with type 2 diabetes who were either ≥30 years of age with a history of symptomatic atherosclerotic cardiovascular events or ≥50 years of age with ≥2 risk factors for cardiovascular disease. The established CVD subgroup included ~65% of all patients. The primary efficacy outcome for these analyses was the composite of cardiovascular mortality, nonfatal MI, or nonfatal stroke.1